newsfilter
← Latest News
GlobeNewswire·

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine